Theravance Biopharma Profit Margin

The latest profit margin for TBPH is 51.58% as of June 2026. That compares with 16.88% in the prior-year period — up 205.6% year over year. That is above the Healthcare sector average of 9.48%. Investors often review this figure alongside Theravance Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, TBPH's profit margin moved from 16.88% to 51.58% — a 205.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Theravance Biopharma's valuation or profitability profile.

Against Healthcare companies, TBPH currently prints 51.58% for profit margin, while the sector average sits near 9.48%. That is roughly 444.1% above the sector mean. Large gaps often invite a closer look at Theravance Biopharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Theravance Biopharma converts resources into returns. At 51.58%, TBPH may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 16.88% in the prior-year period — up 205.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TBPH's profit margin (51.58%), review year-over-year change from 16.88%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.